Answers are grounded in this paper and cite their sources.
Introduction and importance: Pilonidal disease (PD) is a chronic inflammatory condition associated with secondary infection, most commonly with anaerobic, gut-derived bacteria belonging to the Bacteroidota phylum. Glucagon-like peptide-1 (GLP-1) receptor agonists have been found to alter the gut microbiome and increase the abundance of Bacteroidota . Patients with PD often have other comorbidities, such as obesity, which is now commonly treated with GLP-1 receptor agonists. In this report, we describe three patients with new-onset or recurrent PD symptoms after taking GLP-1 receptor agonists. Case presentation: Three patients with PD presented to our Pilonidal Care Clinic with either new-onset gluteal cleft symptoms or recurrent PD. All three had recently started treatment with GLP-1 receptor agonists. Two patients underwent a Gips procedure, and one required incision and drainage. Wound cultures from two patients grew Prevotella , belonging to the phylum Bacteroidota . All wounds healed successfully after intervention, and all patients resumed taking GLP-1 receptor agonists. Clinical discussion: Pilonidal sinuses are commonly infected with Bacteroidota , and initiating GLP-1 receptor agonists can increase the intestinal population of Bacteroidota. A potential temporal relationship between the initiation of GLP-1 receptor agonists and the development of PD symptoms may exist. Patients with PD who are on GLP-1 receptor agonists should be carefully observed. Conclusion: There may be a temporal association between taking GLP-1 receptor agonists and the development of PD symptoms. Recognition of this possibility may lead to early recognition of pilonidal symptoms in patients and to hypothesis generation for future investigation.
No takes yet. Share an insight, caveat, or question.
Jo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: